BDX stock forecast
Our latest prediction for Becton, Dickinson & Co.'s stock price was made on the Nov. 13, 2018 when the stock price was at 234.50$.
In the short term (2weeks), BDX's stock price should outperform the market by 0.40%. During that period the price should oscillate between -2.95% and +3.83%.
In the medium term (3months), BDX's stock price should outperform the market by 0.67%. During that period the price should oscillate between -6.53% and +9.26%.Get email alerts
About Becton, Dickinson & Co.
Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.
At the moment the company generates 17290M USD in revenues.
On its last earning announcement, the company reported a profit of 3.94$ per share.
The book value per share is 79.81$
Three months stock forecastNov. 13, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|